Sweden: Researchers have found in a new study that pre-cardioversion rhythm monitoring using smartphone-based ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which ...

Heart rhythm monitoring in the weeks before cardioversion therapy for atrial fibrillation/atrial flutter reduced the ...

Please provide your email address to receive an email when new articles are posted on . Dronedarone was associated with lower incidence of permanent atrial fibrillation/atrial flutter, more return to ...

Read more about the potential of smartphone-based heart rhythm technology in reducing unnecessary hospital visits.

A team of scientists led by Jarne De Paepe suggests middle-aged men with extensive endurance exercise histories may face ...

New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in ...

ATLANTA - When Michael Woodard of Atlanta retired from his career as a sociology professor, he got more serious about golf. "Since my retirement, I tell people golf is my salvation," Woodard says. The ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of ...

Saint-Etienne, France - Radiofrequency ablation is more effective than treatment with amiodarone for the prevention of atrial flutter recurrence in patients who experienced a first symptomatic episode ...

October 20, 2006 Saint-Etienne, France - Radiofrequency ablation is more effective than treatment with amiodarone for the prevention of atrial flutter recurrence in patients who experienced a first ...